Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.94)
# 1,650
Out of 5,045 analysts
141
Total ratings
54.46%
Success rate
30.69%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $20.19 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $42.31 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $654.04 | +29.96% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.55 | +1,061.29% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.49 | +3,926.85% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $4.35 | +106.90% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $9.23 | +268.36% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $149.61 | +118.57% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $4.23 | +609.22% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $29.70 | +1,812.46% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $419.89 | -33.08% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.10 | +280.95% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.29 | +7,496.90% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $292.00 | +1.03% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $118.44 | -27.39% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $34.02 | +41.09% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.76 | +242.47% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $43.18 | +66.74% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.94 | +157.73% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $92.59 | +8.00% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $203.71 | -1.33% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $68.11 | +24.80% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $12.12 | +164.03% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $23.25 | +833.33% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $36.47 | +31.62% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $16.43 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $449.56 | -65.74% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $51.91 | +123.46% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $5.46 | +1,841.39% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $12.27 | +128.29% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $178.20 | -53.98% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $453.53 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.38 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.19
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $42.31
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $654.04
Upside: +29.96%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.55
Upside: +1,061.29%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.49
Upside: +3,926.85%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $4.35
Upside: +106.90%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $9.23
Upside: +268.36%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $149.61
Upside: +118.57%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $4.23
Upside: +609.22%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $29.70
Upside: +1,812.46%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $419.89
Upside: -33.08%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $2.10
Upside: +280.95%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.29
Upside: +7,496.90%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $292.00
Upside: +1.03%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $118.44
Upside: -27.39%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $34.02
Upside: +41.09%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $8.76
Upside: +242.47%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $43.18
Upside: +66.74%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.94
Upside: +157.73%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $92.59
Upside: +8.00%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $203.71
Upside: -1.33%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $68.11
Upside: +24.80%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $12.12
Upside: +164.03%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $23.25
Upside: +833.33%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $36.47
Upside: +31.62%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $16.43
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $449.56
Upside: -65.74%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $51.91
Upside: +123.46%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $5.46
Upside: +1,841.39%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $12.27
Upside: +128.29%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $178.20
Upside: -53.98%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $453.53
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.38
Upside: -